Werewolf Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
HOWL Nasdaq 2836 werewolftx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Werewolf Therapeutics, Inc.

Here's Why We're A Bit Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Situation - May 14th, 2026 5:23 am
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates - May 7th, 2026 2:05 pm
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates - Mar 27th, 2026 5:00 am
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives - Feb 24th, 2026 2:09 pm
Werewolf Therapeutics (HOWL) Eyes 2026 Catalysts Following FDA Guidance and Encouraging INDUKINE Results - Jan 13th, 2026 7:56 am
Werewolf Therapeutics Announces Pipeline and Business Updates - Dec 18th, 2025 6:00 am
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know - Dec 15th, 2025 10:00 am
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting - Nov 7th, 2025 7:00 am
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Nov 4th, 2025 5:00 am
Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake - Oct 31st, 2025 6:58 am
Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised - Oct 29th, 2025 11:45 am
BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy - Oct 28th, 2025 12:26 pm
Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil - Oct 23rd, 2025 12:54 pm
Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why - Oct 23rd, 2025 10:00 am
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer - Oct 8th, 2025 6:00 am
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting - Oct 3rd, 2025 7:00 am
3 Promising Penny Stocks With Market Caps Under $700M - Sep 25th, 2025 12:05 pm
Werewolf Therapeutics, Inc. (HOWL) Just Flashed Golden Cross Signal: Do You Buy? - Sep 8th, 2025 3:03 pm
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference - Sep 2nd, 2025 6:00 am
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - Aug 14th, 2025 5:00 am